Clinical Trials Browser

Sarcoma, Ewing

Osteosarcoma

Meningioma, Central Nervous System Neoplasms

Brain Neoplasms, Carcinoma, Renal Cell

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Carcinoma, Renal Cell

Neoplasm Metastasis

Carcinoma, Renal Cell

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

Carcinoma, Renal Cell

Metastatic Squamous Non-Small Cell Lung Carcinoma

Glioblastoma, Gliosarcoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular, Recurrence

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Carcinoma, Renal Cell

Neoplasm Metastasis

Recurrence, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Metastatic Castration-resistant Prostate Cancer

Carcinoma, Renal Cell

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Carcinoma, Renal Cell

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Hepatocellular

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Prostatic Neoplasms

Carcinoma, Renal Cell

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Kidney Neoplasms

Locally Advanced Thyroid Gland Carcinoma

Carcinoma, Renal Cell

Neuroendocrine Tumors

Gastro-enteropancreatic neuroendocrine tumor

Clinical Trials

METTSEO

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

SKIPPY 2

CANOPY

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

SAMURAI

LUNG-IST-127

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

International Multicentric Study ARON-1

MegaMOST

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

CaboLu

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

CANIQOL

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

CABOLD

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Autologous Dendritic Cell Vaccine in Kidney Cancer

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Cyto-KIK

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

CARE1

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

CABOGEN

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

CABOTEM